About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Speech in Hepatic Encephalopathy (HE) | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT05425316

Speech in Hepatic Encephalopathy (HE)

This is an observational study that will test the clinical significance of speech features in patients with cirrhosis. It aims to assess if speech is associated with cognitive function at baseline, if...

Lead sponsor: University of Michigan•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Michigan

Collaborators

Winterlight Labs

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Cirrhosis, as diagnosed by imaging, elastography, biopsy, or decompensation
•Able to provide informed consent in English
•Able to provide informed consent in English
•Fibroscan with stiffness \<7 kPa

Exclusion Criteria

•Neurodegenerative disorder (other than hepatic encephalopathy) including Alzheimer's disease and dementia
•Prior stroke or Transischemic Attack (TIA)
•English not primary language for communication
•Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \>5 times the upper limit of normal in the last year
•History of cirrhosis by imaging or histology or clinical decompensation
•Neurodegenerative disorder (other than hepatic encephalopathy) including Alzheimer's disease and dementia
•Prior stroke or TIA

Related studies

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)

NCT06483737 · Overt Hepatic Encephalopathy

Correlation Between Serum Albumin Level and Severity of Hepatic Encephalopathy in Patients With Chronic Liver Disease in Sohag University Hospital

NCT06953921 · Hepatic Encephalopathy

RECRUITINGPhase 2

Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement

NCT06052176 · Cirrhosis, Hepatic Encephalopathy

RECRUITINGPhase 4

Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose

NCT04073290 · Hepatic Encephalopathy, Cirrhosis, Liver, and more

Safety and Efficacy of Fecal Microbiota Transplantation

NCT04014413 · Crohn Disease, Ulcerative Colitis, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 26, 2024Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment251

Start dateOct 2021

Last updatedJul 26, 2024

Condition

Hepatic Encephalopathy

Locations shown

University of Michigan Hepatology and Transplant Clinic

Ann Arbor, Michigan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 26, 2024Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions